Skip to main content
. 2022 May 5;13:2476. doi: 10.1038/s41467-022-30162-5

Fig. 4. Neutralizing antibodies of HCWs receiving three doses of BNT162b2 vaccine.

Fig. 4

a Neutralizing antibody responses of HCWs (n = 59) were analyzed with a microneutralization test against SARS-CoV-2 isolates representing D614G, Delta and Omicron BA.1 variants. Serum samples were collected before the first vaccine dose and three weeks after the second and the third vaccine dose. Additionally, follow-up serum samples were collected 3, 6, and 8 months after the second vaccine dose. A vaccinee with a PCR-confirmed SARS-CoV-2 infection after vaccination is marked with red dots. b Neutralization titers against D614G, Delta, and Omicron BA.1 variants after the second and third vaccine doses were compared. Geometric mean, shown as a line with geometric SD, is indicated above the figure with the percentage of positive samples when neutralization titer ≥20 is considered positive. Differences between neutralization titers were analyzed with two-sided Wilcoxon signed-rank test and p-values <0.05 were considered statistically significant. P-values <0.0001 are marked with ****. c Amino acid changes in Delta and Omicron BA.1 compared to Wuhan Hu-1 sequence are shown in trimeric SARS-CoV-2 spike protein structure (PDB: 6VXX). Substitutions are highlighted with magenta and deletions with orange. Changes located in the receptor-binding domain are bolded.